Keywords: update, fda, advisers, back, forest, memantine, moderate-to-severe

UPDATE: US FDA advisers back Forest's memantine in moderate-to-severe Alzheimer's

Article | 06 October 2003

• Print This

Forest Laboratories moved its Alzheimer's therapy Namenda (memantine) one step closer to the US market when the Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.